Prognostic value of serum soluble interleukin‐23 receptor and related T‐helper 17 cell cytokines in non‐small cell lung carcinoma

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractThe signaling of interleukin (IL)-23 and its receptor (IL-23R) play a crucial role in the development of cancers. However, the clinical significance of human serum soluble IL-23R (sIL-23R) and its relationship with IL-23 are still not explored in non-small cell lung cancer (NSCLC). In our study, sIL-23R was first identified in the serum of NSCLC patients, but not in healthy controls, by proteomics. The IL-23R mRNA and protein were upregulated in NSCLC cell lines and tissues tested by quantitative PCR, western blot analysis and immunohistochemistry. The levels of sIL-23R, IL-23, and IL-17 in 195 NSCLC patients' serum were determined by ELISA, and high levels of sIL-23R were significantly associated with advanced N stage (P = .039), clinical stage (P = .007), and poor 5-year survival rate. In vitro, sIL-23R was shown binding to IL-23 and the balance could affect patients' N and T stage, overall survival, and downstream cytokine IL-17 in a potential antagonistic relationship. Although sIL-23R, IL-23, and IL-17 were all associated with poor prognosis, only the sIL-23R/IL-23 ratio (hazard ratio, 1.945; 95% confidence interval, 1.147-3.299; P = .014) was found to be an independent factor for prognosis. Therefore, we identified fragments of soluble cytokine receptor of IL-23R with affinity ability to its natural ligand IL-23 in NSCLC patients' serum. The balance between the 2 antagonists can work as a potential prognostic serum marker. K E Y W O R D Scombination, IL-23, NSCLC, prognosis, sIL-23R [Correction added on 15 April 2020, after first online publication: Affiliation 4 was revised by adding "the Second Affiliated

Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma

“…The interference of the soluble form of cytokine receptors in the cytokine-receptor axis yields the complexity of cytokine signaling and sequential inflammation, which may in turn determine cancer development and progression [ 14 , 26 ]. Numerous studies, therefore, have assessed the potentiality of soluble forms of receptors as diagnostic and survival predictors using patients’ blood samples [ 17 , 18 , 27 – 30 ]; in fact, serum-soluble interleukin-2 receptor has been widely utilized as an adjunct to the diagnosis and a response evaluation of malignant lymphoma in the clinical setting [ 30 ]. In the current study, the combination of sCD74 and MIF was a significant survival predictor for melanoma patients with advanced stage.…”

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade

“…The CD4 + T cell subsets regulate tumor growth differently [ 59 ]. Th1 cells in tumors protect the host against tumor growth, whereas Th17 and Treg cells are usually associated with progression of the disease, and Th2 cells do not correlate with clinical outcomes in many cases [ 59 , 60 , 61 , 62 , 63 ]. The anti-CTLA-4 treatment upregulated the frequency of Th1, Th2, Th17, and Treg cells in TC-1/dCD80-1-induced tumors.…”

Association between IL-23R rs11209026 Gene polymorphism and soluble interleukin 23 receptor (△9) in Iraqi patients with and without lupus nephritis

“…sIL-23R affects Th17 differentiation and stability because it causes the failure of STAT3 signaling, thus preventing excessive immune inflammation in the body and reducing Th17dependent disease damage (Raymond et al, 2015). Recently, Liu et al (Liu et al, 2020) demonstrated sIL-23/sIL-23R as a new serological marker for predicting disease progression as well as using sIL-23R (D9) to predict inflammatory diseases. In our previous work, as well as a number of studies (Larosa et al, 2019;Vukelic et al, 2020Vukelic et al, , 2019 we demonstrated an elevated IL-23 level in patients with SLE, especially those who develop lupus nephritis.…”